Hyundai Bioscience Co., Ltd.

KOSDAQ 048410.KQ

Hyundai Bioscience Co., Ltd. EBIT Margin for the year ending December 31, 2023: -149.60%

Hyundai Bioscience Co., Ltd. EBIT Margin is -149.60% for the year ending December 31, 2023, a 29.38% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Hyundai Bioscience Co., Ltd. EBIT Margin for the year ending December 31, 2022 was -211.83%, a -15.85% change year over year.
Hyundai Bioscience Co., Ltd. EBIT Margin for the year ending December 31, 2021 was -182.86%, a -174.16% change year over year.
Hyundai Bioscience Co., Ltd. EBIT Margin for the year ending December 31, 2020 was -66.70%, a -929.23% change year over year.
Hyundai Bioscience Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 8.04%, a -34.09% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

KOSDAQ: 048410.KQ

Hyundai Bioscience Co., Ltd.

CEO	Jong-Won Choi
IPO Date	Aug. 28, 2002
Location	South Korea
Headquarters	Academic Cooperation Building
Employees	63
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Cosmetics Personal Care Pharmaceuticals Plastics

Description

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The company was founded in 2000 and is based in Seoul, South Korea.

Key trends

Past 5 years